efeitos da associação estro-androgênica em mulheres na pós-menopausa effects of the association of estrogen and androgen in postmenopausal women
Clicks: 535
ID: 199541
2005
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.1
/100
535 views
86 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #5 of 101 articles by views in 2018 international conference on information technologies, infotech 2018 - proceedings
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJETIVO: avaliar os efeitos da associação de estrogênios e androgênios sobre a qualidade de vida e a sexualidade de mulheres durante o climatério. MÉTODOS: foram incluídas 96 pacientes com sintomas vasomotores e disfunção sexual na pós-menopausa. As mulheres foram aleatoriamente divididas em três grupos de tratamento com 32 pacientes cada: placebo, estrogênios conjugados eqüinos (0,625 mg por dia) e associação de estrogênios conjugados eqüinos (0,625 mg por dia) e de metiltestosterona (2,5 mg por dia). O tratamento foi realizado por três meses. A avaliação da qualidade de vida e da sexualidade foi realizada por entrevista usando o Questionário de Saúde da Mulher (QSM) e o Questionário Simplificado sobre Sexualidade, antes e após o tratamento. Alguns parâmetros do risco cardiovascular, o eco endometrial e a toxidade hepática foram avaliados. Para análise dos dados aplicou-se o teste ANOVA, seguido pelo teste post hoc de Fisher e teste de Shapiro-Wilk. RESULTADOS: houve melhora nos parâmetros do QSM nos grupos que receberam estrogenioterapia isolada e associada ao androgênio em comparação ao grupo placebo. Entretanto, não houve diferença entre os três grupos em relação às questões referentes aos sintomas somáticos. A associação estro-androgênica foi superior ao estrogênio isolado nas questões relacionadas com função sexual (média da pontuação: 64 vs 67; p<0,05) e humor deprimido (média da pontuação: 75 vs 80; p<0,05). No grupo que recebeu a terapia estro-androgênica, houve redução do colesterol total (212±42 e 194±43, antes e após o tratamento, respectivamente) e do HDL-colesterol (56±16 e 48±14, antes e após o tratamento, respectivamente), bem como discreto aumento do eco endometrial (4,7±2,3 e 5,5±2,3 antes e após o tratamento, respectivamente). Não foi constatada alteração significante das enzimas hepáticas entre os grupos, durante o período de estudo. CONCLUSÕES: a associação estro-androgênica resultou em melhora na qualidade de vida e nos distúrbios sexuais. Este efeito foi superior à estrogenioterapia isolada e ao placebo. O efeito do tratamento estro-androgênico foi mais marcante nos itens de humor deprimido e de função sexual no questionário QSM.
PURPOSE: to evaluate the effects of the association of estrogen and androgen on the quality of life and sexuality of women during climacterium. METHODS: ninety-six postmenopausal women with vasomotor symptoms and sexual dysfunction were included. The participants were randomly divided into three treatment groups with 32 pacients each: placebo, conjugated equine estrogens (CEE) (0.625 mg per day) and CEE (0.625 mg per day) associated with methyltestosterone (2.5 mg per day). The length of the treatment period was three months. The Women Health Questionnaire (WHQ) and the Modified Sexuality Questionnaire were applied to evaluate the quality of life and sexuality before and after the treatment. Some parameters of cardiovascular risk, endometrial echo and hepatic toxicity were evaluated. ANOVA was used for data analysis followed by the Fisher test and the Shapiro-Wilk post hoc test. RESULTS: the improvement in WHQ parameters was significant in the hormonal treatment groups (CEE and CEE + methyltestosterone) compared to the placebo group. However, there were no differences in somatic symptoms among the three groups. The association of estrogen with androgen significantly improved sexual function (score (mean): 64 vs 67, p<0.05) and depressive humor (score (mean): 75 vs 80, p<0.05) compared to estrogen alone. This therapy also presented a large number of WHQ questions with a high score (p<0.05). The use of CEE associated with methyltestosterone decreased the total cholesterol (212±42 and 194±43, before and after the treatment, respectively) and HDL colesterol (56±16 and 48±14, before and after the treatment, respectively), and slightly increased the endometrial echo (4.7±2.3 and 5.5±2.3, before and after the treatment, respectively). No signifcant changes in liver enzymes during the treatment period was detected. CONCLUSIONS: estrogen associated with methyltestosterone resulted in significant improvement in the quality of life and sexuality of postmenopausal women. This effect was superior to estrogen alone and placebo. The effect of treatment with the estrogen-androgen association was evident regarding depressive humor and sexual function questions of the WHQ.
PURPOSE: to evaluate the effects of the association of estrogen and androgen on the quality of life and sexuality of women during climacterium. METHODS: ninety-six postmenopausal women with vasomotor symptoms and sexual dysfunction were included. The participants were randomly divided into three treatment groups with 32 pacients each: placebo, conjugated equine estrogens (CEE) (0.625 mg per day) and CEE (0.625 mg per day) associated with methyltestosterone (2.5 mg per day). The length of the treatment period was three months. The Women Health Questionnaire (WHQ) and the Modified Sexuality Questionnaire were applied to evaluate the quality of life and sexuality before and after the treatment. Some parameters of cardiovascular risk, endometrial echo and hepatic toxicity were evaluated. ANOVA was used for data analysis followed by the Fisher test and the Shapiro-Wilk post hoc test. RESULTS: the improvement in WHQ parameters was significant in the hormonal treatment groups (CEE and CEE + methyltestosterone) compared to the placebo group. However, there were no differences in somatic symptoms among the three groups. The association of estrogen with androgen significantly improved sexual function (score (mean): 64 vs 67, p<0.05) and depressive humor (score (mean): 75 vs 80, p<0.05) compared to estrogen alone. This therapy also presented a large number of WHQ questions with a high score (p<0.05). The use of CEE associated with methyltestosterone decreased the total cholesterol (212±42 and 194±43, before and after the treatment, respectively) and HDL colesterol (56±16 and 48±14, before and after the treatment, respectively), and slightly increased the endometrial echo (4.7±2.3 and 5.5±2.3, before and after the treatment, respectively). No signifcant changes in liver enzymes during the treatment period was detected. CONCLUSIONS: estrogen associated with methyltestosterone resulted in significant improvement in the quality of life and sexuality of postmenopausal women. This effect was superior to estrogen alone and placebo. The effect of treatment with the estrogen-androgen association was evident regarding depressive humor and sexual function questions of the WHQ.
| Reference Key |
filho2005revistaefeitos
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Justino Mameri Filho;Mauro Abi Haidar;José Maria Soares Júnior;Edmund Chada Baracat |
| Journal | 2018 international conference on information technologies, infotech 2018 - proceedings |
| Year | 2005 |
| DOI |
10.1590/S0100-72032005000300004
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
ZincirX productsfrom the team behind Journament
-
PatentYazar
Patent drafts for the EPO, USPTO and TürkPatent
From inventor notes to a DOCX draft: description, claims, abstract. The machine drafts, the attorney signs.
See how it works (opens in a new tab) -
Projenator
Have a project idea? Score and plan it with AI
AI scores your idea in five dimensions and builds a phased plan. Your first project is free, no card needed.
Start your first project (opens in a new tab)
Cookies
We use strictly necessary cookies to run the site and keep you signed in. With your permission we would also use Google Analytics to see how the site is used, and Google AdSense to show ads on journal and article pages. Both stay off unless you accept, and you can change your mind at any time. How we use cookies · KVKK notice (Türkiye)
Cookie settings
Your session, form security (XSRF) and this choice; if you came through a member's referral link, its code for 30 days (referral_token). Journament's own cookies only.
Google Analytics 4 (Google LLC, USA): measures which pages are visited; the _ga and _ga_* cookies are kept for up to 2 years.
Google AdSense (Google LLC, USA): shows, measures and may personalise ads on journal, article and home pages; the __gads, __gpi and __eoi cookies are kept for up to 13 months.
Comments
No comments yet. Be the first to comment on this article.